Acute Promyelocytic Leukemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Acute Promyelocytic Leukemia – Drugs In Development, 2024 report and make more profitable business decisions.
Acute Promyelocytic Leukemia is an aggressive blood cancer affecting the white blood cells known as promyelocytes which are immature white blood cells. It is characterized by thrombocytopenia (low platelets) resulting in thrombosis, excess bleeding, and anemia. It is a sub type of AML (acute myeloid leukemia) and is a medical emergency condition. Infections, bruises, bleeding are common symptoms and when examined blood the levels of platelets, WBC cells are low known as pancytopenia. Retinoids are common class of drugs for treating APL. Tretinoin is commonly prescribed alone or with chemotherapy regimen anthracycline given intravenously. Supportive care also provided as needed.
The Acute Promyelocytic Leukemia drugs in development market research report provide comprehensive information on the therapeutics under development for Acute Promyelocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Promyelocytic Leukemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Acute Promyelocytic Leukemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Acute Promyelocytic Leukemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Acute Promyelocytic Leukemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Acute Promyelocytic Leukemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ADCendo ApSGNI Group Ltd
IFOM-IEO Campus
Novartis AG
OncoVerity Inc
Phebra Pty Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Sinco Pharmaceuticals Holdings Ltd
University of Hong Kong
Veru Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Acute Promyelocytic Leukemia reports